GlassScriptPhysician profile
Ashley M Patel
NPI 1174292056
$10,837.20
in general payments reported to CMS, 2019-2025
27 companies · $1,712 in 2025
The $1,712 reported for 2025 was more than what 90% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,052 · 2022: $2,071 · 2023: $3,264 · 2024: $2,739 · 2025: $1,712.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,621 · Education: $93.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,621.22 |
| Education | $93.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| W. L. Gore & Associates, INC. | $1,951.68 | 2021-2024 | Excluder Conformable Aaa Endoprosthesis With Active Control, Gore Tag Conformable Thoracic Stent Graft, Gore Tag Conformable Thoracic Endoprosthesis |
| Neurocrine Biosciences, INC. | $1,332.04 | 2021-2025 | Ingrezza |
| Alkermes, INC. | $1,084.79 | 2021-2025 | Aristada, Lybalvi |
| Vanda Pharmaceuticals INC. | $956.40 | 2021-2025 | Fanapt, Hetlioz |
| Teva Pharmaceuticals USA, INC. | $856.58 | 2022-2025 | Austedo Xr, Uzedy, Austedo |
| Abbvie INC. | $824.99 | 2021-2025 | |
| Boston Scientific Corporation | $657.35 | 2022-2025 | Watchman Flx, Watchman Access System, Baylis Medical Company Radiofrequency Puncture Generator |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $528.51 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $501.13 | 2023-2025 | Rexulti, Abilify Maintena, Nuedexta |
| Supernus Pharmaceuticals, INC. | $428.50 | 2022-2024 | Qelbree, Qelbree |
| Idorsia Pharmaceuticals US INC | $245.02 | 2022-2025 | Quviviq, Quviviq |
| Axsome Therapeutics, INC. | $234.97 | 2022-2025 | Auvelity |
| Lundbeck LLC | $202.77 | 2021-2025 | Rexulti |
| Inari Medical, INC. | $182.08 | 2023-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Janssen Pharmaceuticals, INC | $125.55 | 2021-2024 | Invega Sustenna, Invega Trinza, Invega |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $116.87 | 2021-2022 | |
| Bard Peripheral Vascular, INC. | $112.94 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $85.87 | 2023-2024 | Trintellix |
| Owp Pharmaceuticals, INC. | $84.87 | 2023-2025 | Subvenite, Lamotrigine |
| Indivior INC. | $76.91 | 2024 | Perseris |
| E.R. Squibb & Sons, L.L.C. | $65.35 | 2024-2025 | Cobenfy |
| Edwards Lifesciences Corporation | $53.13 | 2021-2022 | |
| Corium, LLC | $37.87 | 2025 | Azstarys |
| Avanir Pharmaceuticals, INC. | $34.16 | 2022 | |
| Noven Therapeutics, LLC | $32.46 | 2024-2025 | Secuado, Xelstrym |
| Medtronic, INC. | $12.79 | 2021 | |
| Eisai INC. | $11.62 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.